You just read:

Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase 2 Data Demonstrating 11-Month Duration-of-Action After a Single Dose in Patients With Glaucoma

News provided by

Envisia Therapeutics

Feb 03, 2017, 08:45 ET